Pharmaceuticals, Inc. (NASDAQ: SVNT) and its wholly owned subsidiary, Savient
Pharma Ireland Ltd., today announced that the European Commission has granted
a marketing authorization for KRYSTEXXA^® (pegloticase) for the treatment...
Savient Pharma (NASDAQ: SVNT) announced today that David Meeker, M.D., President and Chief
Executive Officer of Genzyme, a Sanofi Company, has been elected to Savient's
Board of Directors, effective January 7, 2013. In addition, Savient...
Savient Pharmaceuticals, Inc.
(NASDAQ: SVNT) today announced results from new post-hoc analyses of
KRYSTEXXA^® (pegloticase) pivotal Phase III and open-label extension trials
that reinforced the health-related quality of life (HRQOL) benefits...
(NASDAQ: SVNT) today announced that new data from an open-label extension
(OLE) study published in the Annals of the Rheumatic Diseases reinforced the
safety and efficacy profile of KRYSTEXXA^® (pegloticase) treatment...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.